CYP induction assays – which way to go?
5 September 2018
In drug discovery and development, there are often several options available for addressing research questions, which may vary considerably in laboriousness, costs and the level of data they produce. Therefore, it is important to choose the right study set up at the right time to obtain correct and relevant answers for the project. As an example of different study approaches, let’s have a look at alternatives for studying CYP enzyme induction in vitro.Read more
Microsampling in in vivo PK studies
5 July 2018
Microsampling technology in drug discovery and development has been gaining a serious foothold within the industry over the last decade. We at Admescope have been providing microsampling as a part of our in vivo PK services for well over a year now and this feels like a good time to let Dr Janne Mannila, our Head of In vivo PK studies share his experiences with microsampling over an interview.Read more
In vitro toxicology screening in drug development
20 March 2018
Prior to IND approval drug candidates must go through a comprehensive battery of in vitro and in vivo toxicology testing to maximise safety in clinical trials. For ethical reasons and the costly nature of the in vivo animal tests the pharmaceutical industry relies more and more on in vitro methods for toxicity testing especially in drug discovery phase. To elucidate this topic further, we interviewed an expert on the subject, Dr Sanna-Mari Aatsinki.Read more
2017 – Hard work and good times
17 January 2018
The twelve months of the year 2017 rushed through like Usain Bolt, faster than ever and celebrating with hands in the air on the way. Or in other words, it was a very nice year for Admescope, being the strongest period in our history, with 20% increase in revenue and tens of new satisfied customers.Read more
The new FDA draft guidance on DDI studies – how does it affect in vitro studies?
1 December 2017
Recently FDA released new draft guidance on drug-drug interaction (DDI) studies. Compared to the previous one issued in 2012, also the structure is revised as there is now two complementary documents. The “In Vitro Metabolism- and Transporter –Mediated Drug-Drug Interaction Studies” focuses on in vitro approaches to evaluate potential interaction risk,Read more